特殊状态人群中亚胺培南-西司他丁的群体药动学研究进展  

Research advance of population pharmacokinetics of imipenem-cilastatin in special status populations

作　　者：左建丽 何瑶[1] 李福书 陈兴 郑晓媛 ZUO Jianli;HE Yao;LI Fushu;CHEN Xing;ZHENG Xiaoyuan(Dept.of Pharmacy,Chongqing Emergency Medical Center/Chongqing University Central Hospital,Chongqing 400014,China)

机构地区：[1]重庆市急救医疗中心/重庆大学附属中心医院药剂科,重庆400014

出　　处：《中国药房》2022年第9期1141-1146,共6页China Pharmacy

基　　金：重庆市技术创新与应用示范(社会民生类)一般项目(No.cstc2018jscx-msybX0172);重庆市卫生计生委医学科研项目(No.2017ZDXM023)。

摘　　要：亚胺培南-西司他丁为广谱碳青霉烯类抗菌药物,已在临床广泛应用,但其在特殊状态人群[本文特指连续性肾脏替代治疗(CRRT)患者、体外膜肺氧合(ECMO)患者、病情危重的烧伤患者以及新生儿和儿童]的个体化给药方案制订中缺乏相应指南和专家共识。本文总结亚胺培南-西司他丁在特殊状态人群中的群体药动学研究,推荐亚胺培南-西司他丁剂量为:CRRT患者给予1~3 g/d;烧伤患者给予500 mg~1 g,q6 h;ECMO患者给予750 mg~1 g,q6 h;新生儿给予20 mg/kg,q8 h或25 mg/kg,q8 h;儿童给予25 mg/kg,q6 h。Imipenem-cilastatin is a broad-spectrum carbapenem antibiotic drug that has been widely used in clinical practice,but there is a lack of guidelines and expert consensus on the development of individualized regimens for special status populations[e.g.continuous renal replacement therapy(CRRT)patients,extracorporeal membrane oxygenation(ECMO)patients,critically ill burn patients,neonates and children].In this paper,by searching population pharmacokinetics research of imipenemcilastatin in special status populations,it is recommended that imipenem-cilastatin is given 1 to 3 g/d for CRRT patients;500 mg to 1 g,q6 h for burn patients;750 mg to 1 g,q6 h for ECMO patients;20 mg/kg or 25 mg/kg,q8 h for neonates;and 25 mg/kg,q6 h for children.

关 键 词：亚胺培南-西司他丁 群体药动学 连续性肾脏替代治疗 体外膜肺氧合 危重症 特殊人群 剂量优化 

分 类 号：R969[医药卫生—药理学] R978.1[医药卫生—药学]